SCHEMBL1676211

SCHEMBL1676211

O=C(O)c1ccc(Cn2cc(-c3ccc(Cl)cc3Cl)nc2/C=C/c2ccc(Br)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
CRHBP P24387 1/20 0.44
RAB9A P51151 1/20 0.44
CRHR2 Q13324 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ENPP2 Q13822 1/20 0.42
DHODH Q02127 1/20 0.41
POLB P06746 3/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
SRD5A2 P31213 1/20 0.38
ALDH1A1 P00352 1/20 0.37
MAPK10 P53779 1/20 0.37
GPR183 P32249 1/20 0.37
MRGPRX4 Q96LA9 1/20 0.36
ABL1 P00519 1/20 0.36
BCR P11274 1/20 0.36
DRD2 P14416 1/20 0.36
EBP Q15125 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1676214 1.00 KDM4E (0.44) KDM4ENPC1CRHBPRAB9ACRHR2
SCHEMBL6514437 0.92 DHODH (0.37) KDM4ENPC1CRHBPRAB9ACRHR2
SCHEMBL6514442 0.92 DHODH (0.37) KDM4ENPC1CRHBPRAB9ACRHR2
SCHEMBL1481483 0.91 KDM4E (0.44) KDM4ENPC1CRHBPRAB9ACRHR2
SCHEMBL1481480 0.91 KDM4E (0.44) KDM4ENPC1CRHBPRAB9ACRHR2
SCHEMBL1482277 0.89 DRD2 (0.49) POLBALDH1A1MAPK10DRD2MAPT
SCHEMBL1482273 0.89 DRD2 (0.49) POLBALDH1A1MAPK10DRD2MAPT
SCHEMBL1481188 0.89 SMN1; SMN2 (0.47) KDM4ENPC1CRHBPRAB9ACRHR2
SCHEMBL1481186 0.89 SMN1; SMN2 (0.47) KDM4ENPC1CRHBPRAB9ACRHR2
SCHEMBL1676385 0.88 KDM4E (0.45) KDM4ENPC1CRHBPRAB9ACRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 US disclosed
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 US disclosed
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 US disclosed
EP-1730118-A1 SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE Transtech Pharma, Inc. (US) 2006-12-13 EP disclosed
WO-2005080346-A1 SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE TRANSTECH PHARMA, INC. (US) 2005-09-01 WO disclosed
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use PTPRO, PTPN5, PTPRE KDM4E 733/4885NPC1 3228/4885CRHBP 4719/4885
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use PTPRO, PTPN5, PTPRE KDM4E 733/4885NPC1 3228/4885CRHBP 4719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.